Path analysis of biomarkers for cognitive decline in early Parkinson's disease.

ABSTRACT: Clinical and biochemical diversity of Parkinson's disease (PD) and numerous demographic, clinical, and pathological measures influencing cognitive function and its decline in PD create problems with the determination of effects of individual measures on cognition in PD. This is particularly the case where these measures significantly interrelate with each other producing intricate networks of direct and indirect effects on cognition. Here, we use generalized structural equation modelling (GSEM) to identify and characterize significant paths for direct and indirect effects of 14 baseline measures on global cognition in PD at baseline and at 4 years later. We consider 269 drug-naïve participants from the Parkinson's Progression Marker Initiative database, diagnosed with idiopathic PD and obs

SUBMITTER: Gramotnev DK 

PROVIDER: S-EPMC9106174 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature